---
title: "Renal Safety Checkpoint for Early High‑Intensity Statins in Critically Ill ACS Patients"
id: "medrxiv-0-a-renal-safety-checkpoint-for-early-high-intensity-statin-therapy-in-critically"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-a-renal-safety-checkpoint-for-early-high-intensity-statin-therapy-in-critically"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1?rss=1"
published_at: "2026-08-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Renal Safety Checkpoint for Early High‑Intensity Statins in Critically Ill ACS Patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-a-renal-safety-checkpoint-for-early-high-intensity-statin-therapy-in-critically
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1?rss=1)
- **Published At:** 2026-08-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study emulated an active-comparator target trial using three critical care databases (MIMIC‑IV, eICU, and MIMIC‑III) to evaluate renal safety of early **high‑intensity statin** versus **moderate‑intensity statin** therapy in critically ill adults with acute coronary syndrome (ACS), acute myocardial infarction, or after percutaneous coronary intervention. - Inclusion required initiation of either high‑ or moderate‑intensity statin within 24 hours of care; the primary outcome was 7‑day **KDIGO** stage 2 or 3 **acute kidney injury (AKI)** or incident **renal replacement therapy (RRT)**. - The pooled cohort included 5,178 patients; 761 met the primary outcome and 223 initiated RRT within 7 days. - After database‑specific propensity scoring, overlap weighting, and standardization, standardized 7‑day risks were 17.40% with high‑intensity therapy versus 15.01% with moderate intensity (risk difference 2.39 percentage points; 95% CI, −0.23 to 5.05; risk ratio 1.16; 95% CI, 0.99–1.39). - Risk separation was larger in subgroups with high **hemodynamic instability** (risk difference 5.78 percentage points; 95% CI, 1.56–9.74) and high **drug‑interaction burden** (risk difference 6.24 percentage points; 95% CI, −0.44 to 12.19). - For the RRT endpoint, there was a 1.33 percentage‑point increased risk with high‑intensity statins (95% CI, 0.18 to 2.67). - Authors propose a **renal safety checkpoint** framework that integrates kidney status, perfusion/hemodynamics, and co‑medication interaction burden to guide early statin intensity reassessment in the ICU; this aims to retain intensive lipid lowering for suitable patients while identifying a high‑risk window for temporary moderation. - Robustness was evaluated with longitudinal analyses, bootstrap resampling, source omission, endpoint sensitivity checks, and multiple safety domain assessments. - The report is a preprint and has not been peer reviewed; specific methodological and limitation details beyond the abstract are not reported in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=hjuiT1xvZgmMqL8gYjn8iZ9_AANbkn3fxo1P6cSU_JM-1786131062.4360733-1.2.1.1-X1zOTHpyHiKYPCLuKTbwNSHsEHrrcBYwsqQlHsppJWA) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # A Renal Safety Checkpoint for Early High Intensity Statin Therapy in Critically Ill Patients With Acute Coronary Syndrome: A Multidatabase Target Trial Emulation Kaizong Huang, Xiaohan Zheng, Jie Liu, Chenyang Wu, Hong Sun doi: https://doi.org/10.64898/2026.08.05.26359828 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Kaizong Huang 1 Nanjing First Hospital, China Pharmaceutical University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kaizong%2BHuang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Huang%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKaizong%2BHuang%2B) Xiaohan Zheng 2 Fuzhou University Affiliated Provincial Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Xiaohan%2BZheng%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zheng%20X&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AXiaohan%2BZheng%2B) Jie Liu 3 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jie%2BLiu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Liu%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJie%2BLiu%2B) Chenyang Wu 1 Nanjing First Hospital, China Pharmaceutical University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chenyang%2BWu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wu%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChenyang%2BWu%2B) Hong Sun 2 Fuzhou University Affiliated Provincial Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hong%2BSun%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sun%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHong%2BSun%2B) * For correspondence: sunhong7777@fjmu.edu.cn * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1274155/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1274155/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1274155/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1274155/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1274155/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: High intensity statins are foundational after acute coronary syndrome (ACS), yet intensive care unit prescribing occurs while renal reserve, perfusion, and interacting therapies are changing. We tested a renal safety checkpoint integrating kidney status, hemodynamic instability, and drug interaction burden to identify when statin intensity may become nonexchangeable. Methods: We emulated an active-comparator target trial across MIMIC-IV, eICU, and MIMIC-III. Critically ill adults with ACS, acute myocardial infarction, or percutaneous coronary intervention who received high- or moderate-intensity statins within 24 hours were included. The primary outcome was 7-day KDIGO stage 2 or 3 acute kidney injury or incident renal replacement therapy. Eligibility, time zero, treatment assignment, and follow-up were aligned. Database-specific propensity scores, overlap weighting, and standardization addressed confounding and treatment overlap. Safety domains, longitudinal analyses, bootstrap resampling, source omission, and endpoint sensitivities assessed robustness. Results: Among 5,178 patients, 761 developed the primary outcome, including 223 who initiated renal replacement therapy. Standardized risks were 17.40% with high-intensity therapy and 15.01% with moderate-intensity therapy (risk difference, 2.39 percentage points [95% confidence interval (CI), -0.23 to 5.05]; risk ratio, 1.16 [95% CI, 0.99 to 1.39]). Risk separation was greatest with high hemodynamic instability (5.78 percentage points [95% CI, 1.56 to 9.74]) and high drug-interaction burden (6.24 percentage points [95% CI, -0.44 to 12.19]). Renal replacement therapy showed a 1.33-point risk difference (95% CI, 0.18 to 2.67). Conclusions: This study moves statin safety assessment beyond fixed dose label or isolated creatinine measurement. The findings support a clinically actionable monitoring strategy in which early statin intensity is reassessed against evolving perfusion, kidney status, and interaction burden. This approach preserves intensive lipid lowering for physiologically suitable patients while identifying a high risk window in which temporary moderation. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The author KZH who has passed the Protecting Human Research Participants examination, could access the database. The MIMIC Database obtained Institutional Review Board (IRB) approval and a waiver of informed consent from Beth Israel Deaconess Medical Center, while the eICU Collaborative Research Database was approved with informed consent waiver by the Massachusetts Institute of Technology IRB. Deidentified data were used in this study by credentialed researchers following the PhysioNet Credentialed Health Data Use Agreement. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data analyzed in this study are available from PhysioNet to credentialed users who complete the required training and sign the applicable Data Use Agreement: MIMIC-IV, MIMIC-III, and the eICU Collaborative Research Database, where applicable. Patient-level derived data cannot be redistributed under the data-use terms. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.05.26359770v1 "Change of prognostic nutritional index after three months of initial hemodialysis is a predictor of long-term outcomes for patients with uremia")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.05.26359771v1 "SOFA-2 reclassifies multiorgan dysfunction syndrome in major trauma patients") Posted August 07, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/07/2026.08.05.26359828.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.05.26359828v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/07/2026.08.05.26359828.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) A Renal Safety Checkpoint for Early High Intensity Statin Therapy in Critically Ill Patients With Acute Coronary Syndrome: A Multidatabase Target Trial Emulation Kaizong Huang, Xiaohan Zheng, Jie Liu, Chenyang Wu, Hong Sun medRxiv 2026.08.05.26359828; doi: https://doi.org/10.64898/2026.08.05.26359828 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.05.26359828v1%26text%3DA%2520Renal%2520Safety%2520Checkpoint%2520for%2520Early%2520High%2520Intensity%2520Statin%2520Therapy%2520in%2520Critically%2520Ill%2520Patients%2520With%2520Acute%2520Coronary%2520Syndrome%253A%2520A%2520Multidatabase%2520Target%2520Trial%2520Emulation "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.05.26359828v1%26t%3DA%2520Renal%2520Safety%2520Checkpoint%2520for%2520Early%2520High%2520Intensity%2520Statin%2520Therapy%2520in%2520Critically%2520Ill%2520Patients%2520With%2520Acute%2520Coronary%2520Syndrome%253A%2520A%2520Multidatabase%2520Target%2520Trial%2520Emulation "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.05.26359828v1%26title%3DA%2520Renal%2520Safety%2520Checkpoint%2520for%2520Early%2520High%2520Intensity%2520Statin%2520Therapy%2520in%2520Critically%2520Ill%2520Patients%2520With%2520Acute%2520Coronary%2520Syndrome%253A%2520A%2520Multidatabase%2520Target%2520Trial%2520Emulation%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.05.26359828v1%26title%3DA%2520Renal%2520Safety%2520Checkpoint%2520for%2520Early%2520High%2520Intensity%2520Statin%2520Therapy%2520in%2520Critically%2520Ill%2520Patients%2520With%2520Acute%2520Coronary%2520Syndrome%253A%2520A%2520Multidatabase%2520Target%2520Trial%2520Emulation "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.05.26359828) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.05.26359828v1&count=horizontal&via=&text=A%20Renal%20Safety%20Checkpoint%20for%20Early%20High%20Intensity%20Statin%20Therapy%20in%20Critically%20Ill%20Patients%20With%20Acute%20Coronary%20Syndrome%3A%20A%20Multidatabase%20Target%20Trial%20Emulation&counturl=www.medrxiv.org/content/10.64898/2026.08.05.26359828v1 "Tweet This") ## Subject Area * [Cardiovascular Medicine ](https://www.medrxiv.org/collection/cardiovascular-medicine) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (598) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (889) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (322) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4697) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (466) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (403) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (632) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1599) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15675) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1180) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6894) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (721) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1036) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4873) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1414) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1704) * [Hematology](https://www.medrxiv.org/collection/hematology) (568) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1311) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16163) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1150) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (653) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (707) * [Neurology](https://www.medrxiv.org/collection/neurology) (7057) * [Nursing](https://www.medrxiv.org/collection/nursing) (358) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1060) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1208) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (988) * [Oncology](https://www.medrxiv.org/collection/oncology) (3516) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1016) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (381) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (434) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (458) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (135) * [Pathology](https://www.medrxiv.org/collection/pathology) (696) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1756) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (725) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (753) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5740) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9571) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2334) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1409) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1231) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (629) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (758) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (568) * [Surgery](https://www.medrxiv.org/collection/surgery) (753) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (105) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (300) * [Urology](https://www.medrxiv.org/collection/urology) (278) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments
## Related Clinical Research

- [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md)
- [Ticagrelor versus Prasugrel After PCI for Acute Coronary Syndrome: Multinational Comparative Effec](https://medichelpline.com/clinical-feed/medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [SGLT2 Inhibitors and 90-Day Myocardial Infarction Risk After Total Shoulder Arthroplasty](https://medichelpline.com/clinical-feed/pubmed-42012366.md) (DOI: 10.5435/JAAOS-D-25-01211)
- [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.